AI
IMRX icon

Atria Investments’s Immuneering IMRX Stock Holding History

Atria Investments’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,758
Closed -$56.7K – 2203
2026
Q1 		$56.7K Buy
+10,758
New +$55.1K ﹤0.01% 2023

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Atria Investments's IMRX Position: Q2 2026 in Review

Atria Investments sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 10,758 shares — an estimated $56.7K sold.

Atria Investments first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $56.7K in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Atria Investments reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
  • Atria Investments sold 10,758 Immuneering shares in Q2 2026, an estimated $56.7K.
  • Atria Investments first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
  • Atria Investments's Immuneering position peaked at $56.7K in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.